Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $69.6 million.

  • Corcept Therapeutics' Receivables - Net rose 1659.83% to $69.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.6 million, marking a year-over-year increase of 1659.83%. This contributed to the annual value of $54.0 million for FY2024, which is 3125.5% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Receivables - Net stood at $69.6 million, which was up 1659.83% from $64.6 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Receivables - Net peaked at $69.6 million during Q3 2025, and registered a low of $22.2 million during Q1 2021.
  • Moreover, its 5-year median value for Receivables - Net was $32.6 million (2023), whereas its average is $41.4 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Receivables - Net tumbled by 1680.41% in 2021, and later skyrocketed by 8895.48% in 2024.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Receivables - Net stood at $27.6 million in 2021, then grew by 12.42% to $31.1 million in 2022, then surged by 32.41% to $41.1 million in 2023, then surged by 31.26% to $54.0 million in 2024, then increased by 29.0% to $69.6 million in 2025.
  • Its last three reported values are $69.6 million in Q3 2025, $64.6 million for Q2 2025, and $61.8 million during Q1 2025.